Meridian Bioscience Revenue | VIVO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Meridian Bioscience

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
333 M	318 M	254 M	201 M	51.5 M	52.3 M	46.8 M	195 M	189 M	189 M	174 M	160 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
333 M	46.8 M	180 M

Quarterly Revenue Meridian Bioscience

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1	2010-Q3
56.9 M	56.9 M	67.8 M	111 M	88.3 M	88.3 M	63.5 M	85.3 M	92.9 M	92.9 M	84.8 M	57.3 M	47.4 M	47.4 M	48.4 M	50.2 M	51.5 M	51.5 M	51.7 M	51.7 M	56.5 M	52.3 M	49.7 M	50.1 M	54.1 M	46.8 M	47 M	50.7 M	46.8 M	47.2 M	47.1 M	48.2 M	47.2 M	48 M	46.7 M	47.2 M	48 M	44.8 M	49 M	47.1 M	44.8 M	45.4 M	43.5 M	41.9 M	45.4 M	40.1 M	41.3 M	40.1 M	40.3 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
111 M	40.1 M	55.2 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Diagnostics research industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Enzo Biochem ENZ	31.9 M	-	-8.98 %	$ 14.8 K	USA
QIAGEN N.V. QGEN	2.25 B	-	-	$ 10.6 B	Niderland
Centogene N.V. CNTG	128 M	-	-6.23 %	$ 30.6 M	Germany
DarioHealth Corp. DRIO	22.4 M	$ 6.98	1.51 %	$ 27.8 M	Israel
Charles River Laboratories International CRL	4.02 B	$ 293.35	0.54 %	$ 14.5 B	USA
Aspira Women's Health AWH	343 K	-	-6.19 %	$ 10.5 M	USA
ICON Public Limited Company ICLR	8.25 B	$ 163.58	2.34 %	$ 12.8 B	Irlanda
Brainsway Ltd. BWAY	41 M	$ 14.51	1.61 %	$ 493 M	Israel
Oxford Immunotec Global PLC OXFD	73.7 M	-	-	$ 562 M	Britain
Akumin AKU	750 M	-	-17.87 %	$ 25.9 M	Canada
Accelerate Diagnostics AXDX	11.7 M	-	-61.36 %	$ 2.46 M	USA
Mettler-Toledo International MTD	4.03 B	$ 1 356.23	0.66 %	$ 28 B	Schweiz
Myriad Genetics MYGN	824 M	$ 3.23	1.57 %	$ 299 M	USA
Biocept BIOC	25.9 M	-	-13.05 %	$ 7.29 M	USA
Global Cord Blood Corporation CO	1.24 B	-	-	$ 399 M	China
ENDRA Life Sciences NDRA	6.17 K	$ 5.68	22.58 %	$ 4.47 M	USA
Fluidigm Corporation FLDM	138 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	7.66 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	651 M	-	0.12 %	$ 80.1 M	China
Chembio Diagnostics CEMI	49.5 M	-	0.22 %	$ 16.8 M	USA
National Research Corporation NRC	137 M	$ 21.25	6.2 %	$ 476 M	USA
PRA Health Sciences, Inc. PRAH	3.18 B	-	-	$ 10.7 B	USA
OPKO Health OPK	148 M	$ 1.61	11.18 %	$ 1.21 B	USA
DermTech DMTK	15.3 M	-	-11.32 %	$ 2.94 M	USA
Pacific Biosciences of California PACB	160 M	$ 1.3	3.13 %	$ 390 M	USA
Personalis PSNL	69.6 M	$ 16.83	0.6 %	$ 1.5 B	USA
Quest Diagnostics Incorporated DGX	11 B	$ 239.4	2.07 %	$ 26.6 B	USA
DexCom DXCM	4.66 B	$ 89.71	0.02 %	$ 35 B	USA
Heska Corporation HSKA	257 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	6.37 M	-	-20.0 %	$ 1.06 M	USA
Soleno Therapeutics SLNO	190 M	-	-	$ 2.69 B	USA
Psychemedics Corporation PMD	19.7 M	-	-1.84 %	$ 15.3 M	USA
Motus GI Holdings MOTS	319 K	-	-34.28 %	$ 263 K	Israel
Syneos Health SYNH	5.39 B	-	-	$ 4.46 B	USA
Invitae Corporation NVTA	122 M	-	-	$ 21.2 M	USA
Organovo Holdings ONVO	131 K	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	30.2 M	-	-16.95 %	$ 1.54 M	USA
T2 Biosystems TTOO	7.19 M	-	-39.35 %	$ 313 K	USA
Anixa Biosciences ANIX	210 K	$ 3.05	0.64 %	$ 99 K	USA
Neuronetics STIM	149 M	$ 2.72	0.18 %	$ 179 M	USA
PerkinElmer PKI	2.86 B	-	-0.91 %	$ 14.7 B	USA
Quotient Limited QTNT	38.5 M	-	-11.32 %	$ 1.1 M	Schweiz
Renalytix AI plc RNLX	2.29 M	-	5.66 %	$ 22.7 M	Britain
Interpace Biosciences IDXG	38.7 M	$ 1.45	2.11 %	$ 6.41 M	USA
IQVIA Holdings IQV	16.3 B	$ 271.62	2.95 %	$ 46.7 B	USA
Surmodics SRDX	126 M	-	-	$ 608 M	USA
Quidel Corporation QDEL	1.66 B	$ 13.93	1.45 %	$ 587 M	USA